Axon Therapies
- Industry
- Medical Devices
- Founded Year
- 2014
- Headquarters
- 2326 Walsh Ave, Santa Clara, CA 95051
- Employee Count
- 9
Key People
- Chad Hoskins - President & CEO
- PJ Iranitalab - SVP of Engineering & Operations
- Matthew Stark - VP of Clinical & Regulatory Affairs
- Mark Gelfand - Co-Founder, Chief Technology Officer & Board Member
- Howard Levin MD - Co-Founder, Senior Clinical Advisor & Board Member
Assessment
- Team
-
Aspect: 1 successful MedTech entrepreneur
Summary: The leadership team includes experienced professionals with backgrounds in medical technology and engineering.
The leadership team comprises individuals with significant experience in the medical device industry, including co-founders with prior entrepreneurial success. This expertise positions the company well for navigating the complexities of product development and market entry.
- Clinical Need
-
Aspect: Very Strong
Summary: Addressing heart failure with preserved ejection fraction (HFpEF), a condition with limited treatment options.
HFpEF affects a substantial patient population and currently lacks effective treatments. Axon Therapies' approach offers a novel solution, potentially improving patient outcomes and filling a critical gap in cardiovascular care.
- Competition
-
Aspect: First mover
Summary: Limited direct competition in the specific area of splanchnic nerve ablation for HFpEF.
Axon Therapies appears to be among the first to develop a minimally invasive procedure targeting the splanchnic nerve for HFpEF treatment. This first-mover status allows the company to establish a strong market presence before potential competitors enter the space.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing a novel ablation procedure with associated technical complexities.
While the SAVM procedure offers a promising treatment modality, the development of new medical devices and procedures involves inherent technical challenges, including ensuring safety, efficacy, and regulatory compliance. These factors can influence the speed and success of bringing the product to market.
- Patent
-
Aspect: Strong
Summary: The company has secured patents for its technology.
Holding patents for the SAVM procedure and related technologies provides Axon Therapies with intellectual property protection, potentially preventing competitors from developing similar treatments and allowing the company to capitalize on its innovations.
- Financing
-
Aspect: Medium
Summary: Secured funding from reputable investors but may require additional capital.
While Axon Therapies has attracted investment from notable firms, the capital-intensive nature of medical device development and commercialization may necessitate further fundraising to achieve long-term objectives and market penetration.
- Regulatory
-
Aspect: Running FIH
Summary: Currently conducting first-in-human (FIH) trials.
The company is in the early stages of clinical evaluation, with FIH trials underway. Navigating the regulatory landscape to achieve approvals for broader clinical use involves rigorous testing and compliance, which can be time-consuming and resource-intensive.
Opportunity Rollup
- Odds of Success
- 3.8
- Peak Market Share
- 5.35
- Segment CAGR
- 4.0%
- Market Segment
- Cardiovascular Devices
- Market Sub Segment
- Interventional Cardiology
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.27 |
| 2 | 0.80 |
| 3 | 1.87 |
| 4 | 3.74 |
| 5 | 5.35 |
Key Takeaway
Axon Therapies is pioneering a novel approach to treat HFpEF, addressing a significant unmet need with strong leadership and patent protection, though facing technical and regulatory challenges.